A Phase 1 Study in Healthy Subjects to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Oral Doses of DS-2969b, a Novel GyrB Inhibitor.
about
A Phase 1 Study in Healthy Subjects to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Oral Doses of DS-2969b, a Novel GyrB Inhibitor.
description
2018 nî lūn-bûn
@nan
2018年の論文
@ja
2018年学术文章
@wuu
2018年学术文章
@zh
2018年学术文章
@zh-cn
2018年学术文章
@zh-hans
2018年学术文章
@zh-my
2018年学术文章
@zh-sg
2018年學術文章
@yue
2018年學術文章
@zh-hant
name
A Phase 1 Study in Healthy Sub ...... 2969b, a Novel GyrB Inhibitor.
@en
A Phase 1 Study in Healthy Sub ...... 2969b, a Novel GyrB Inhibitor.
@nl
type
label
A Phase 1 Study in Healthy Sub ...... 2969b, a Novel GyrB Inhibitor.
@en
A Phase 1 Study in Healthy Sub ...... 2969b, a Novel GyrB Inhibitor.
@nl
prefLabel
A Phase 1 Study in Healthy Sub ...... 2969b, a Novel GyrB Inhibitor.
@en
A Phase 1 Study in Healthy Sub ...... 2969b, a Novel GyrB Inhibitor.
@nl
P2093
P2860
P356
P1476
A Phase 1 Study in Healthy Sub ...... 2969b, a Novel GyrB Inhibitor.
@en
P2093
Alexander G Vandell
Cynthia Zamora
George Zhang
Giorgio Senaldi
Justin Dennie
Nobuhisa Masuda
Roohi Gajee
Satoshi Inoue
Yasuo Nagasawa
P2860
P356
10.1128/AAC.02537-17
P407
P577
2018-02-12T00:00:00Z